Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

The more I read this report alleged to be from Flavus, the more nonsense I see in it. It makes more and more sense it came from a Novartis or Pfizer backed source.

Suppose for a moment the information is accurate, though it is obviously anecdotal trash. Then:

1. The 10 patients that dropped out, where did they come from in the pool of 77, the 39, or the new 38 patients who somehow were not in, or refused entry into the trials. I suggest these drop outs could not be helped, even by pona. There is no indication they have been/will be put on Bosulif or any other drug, or that those drugs had been used and were not helpful.

2. Side effects from where, the FDA label? or the patients, or from every other TKI SE info on the market?

3. Treatable, nothing new.

4. Few consider Bosulif the better drug. The IMS data backs this over 6 months of Bosulif data.

5. So what. Nothing illegal. Sounds like Novartis, and BM and PF are getting really scared about market share.

6. Refutes and defeats the claims made in item 4. Illogical.

7. Long way from any real conclusions on this. BTW, Gleevec data shows recent drop in use.

View: The prescription data show the opposite. SE are common to all TKIs, and possibly less so with Pona in that it is intended for use for those that cannot tolerate other TKIs.